Targacept Inc. said yesterday that it has received positive results in the Phase 2b clinical trial of its drug TC-5214 as an augmentation therapy for major depressive disorder. Continued >
Targacept stock jumps after news from drug trial – Winston-Salem Journal
July 16, 2009